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Abstract (250 words): 
Objective: Autoimmune responses to DNA topoisomerase-I (TOP1) are found in a subset of patients 
with scleroderma at high risk for interstitial lung disease (ILD) and mortality. Anti-TOP1 antibodies 
(ATA) are associated with specific HLA-DRB1 alleles, and the frequency of HLA-DR-restricted 
TOP1-specific CD4+ T cells is associated with the presence, severity, and progression of ILD. 
Although this strongly implicates the presentation of TOP1 peptides by HLA-DR in scleroderma 
pathogenesis, the processing and presentation of TOP1 has not been studied.
Methods: We developed a natural antigen processing assay (NAPA) to identify putative CD4+ T cell 
epitopes of TOP1 presented by monocyte-derived dendritic cells (mo-DCs) from six ATA-positive 
patients with scleroderma. Mo-DCs were pulsed with TOP1 protein, HLA-DR:peptide complexes 
were isolated, and eluted peptides were analyzed by mass spectrometry. We then examined the ability 
of these naturally presented peptides to induce CD4+ T cell activation in 11 ATA-positive and 11 
ATA-negative scleroderma patients.
Results: We found that a common set of 10 TOP1 epitopes was presented by mo-DCs from 
scleroderma patients with diverse HLA-DR variants. Sequence analysis revealed shared peptide-
binding motifs within the HLA-DRβ chains of ATA-positive patients and a subset of TOP1 epitopes 
with distinct sets of anchor residues capable of binding to multiple different HLA-DR variants. The 
NAPA-derived epitopes elicited robust CD4+ T cell responses in 73% (8/11) ATA-positive patients, 
and the number of epitopes recognized correlated with ILD severity (p=0.025). 
Conclusion: These findings mechanistically implicate presentation of a convergent set of TOP1 
epitopes in the development of scleroderma.
Introduction
Scleroderma, also called systemic sclerosis, is a complex autoimmune rheumatic disease of 
unknown etiology, characterized by widespread vasculopathy, fibrosis of the skin and internal organs 
(1), and immunological derangements, including the production of autoantibodies to specific nuclear A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
antigens (2). Anti-topoisomerase-I (TOP1) autoantibodies (ATA; also known as anti-Scl-70) are 
present in 20-45% of patients with scleroderma and are associated with diffuse skin involvement, 
pulmonary fibrosis and high mortality (3). ATA production in patients with scleroderma is associated 
with specific HLA-DRB1 alleles (4), implicating CD4+ T helper cells in driving immune responses to 
TOP1. TOP1-specific CD4+ T cells have been detected in the peripheral blood of patients with 
scleroderma (5–8), are HLA-DR restricted, and their frequency is associated with the presence, 
severity, and progression of lung fibrosis (9). Previous attempts to define TOP1 epitopes in patients 
with scleroderma using overlapping peptide/protein fragment libraries or peptides derived from in 
silico prediction have resulted in the identification of scattered epitopes with unspecified biological 
and clinical significance (5–8).  Therefore, although ATA-associated HLA-DRB1 alleles have been 
defined and TOP-I-specific CD4+ T cells have been detected in ATA-positive patients, the 
identification of the TOP1 epitopes driving the autoimmune process has remained elusive.
To overcome current limitations related to the identification and study of autoreactive T cell 
epitopes, we developed a method for identifying the repertoire of naturally processed TOP1 peptides 
presented by antigen presenting cells (APCs) obtained from patients with scleroderma. This approach 
has innovative features compared to traditional epitope-discovery methods, as it harnesses the cellular 
MHC class II antigen processing machinery present in an individual to identify naturally presented 
peptides, without requiring pre-defined knowledge about the target peptide length or HLA status. Our 
analysis of naturally presented TOP1 peptides has revealed unexpected insights into the pathogenesis 
of scleroderma and identified a discrete set of clinically relevant TOP1-specific CD4+ T cell epitopes 
that may inform the future development of antigen-specific diagnostic and therapeutic tools.
Materials and Methods
Human Subjects
Patients in this study were drawn from an observational cohort of patients with scleroderma 
followed at the Johns Hopkins Scleroderma Center. All patients participating in this study met the 
2013 Classification Criteria for Systemic Sclerosis or met at least 3 out of 5 criteria for CREST 
syndrome (12,13). The Johns Hopkins institutional review board approved the study and all patients A
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signed written informed consent. Detailed information about this cohort is provided in the 
supplementary materials and methods. Clinical data are also summarized in Table S1. 
Natural antigen processing assay (NAPA)
Monocyte-derived dendritic cell differentiation and antigen-loading. Peripheral blood mononuclear 
cells (PBMCs) were isolated by density-gradient centrifugation (Ficoll-Paque Plus, GE Healthcare) 
from 40ml of whole blood obtained from 6 ATA-positive patients. CD14 MicroBeads were used to 
positively select CD14+ monocytes and cells were differentiated for 7 days into monocyte-derived 
dendritic cells (mo-DCs), using Mo-DC Differentiation Medium (Miltenyi Biotec). Mo-DCs (2-5 x 
106) were incubated overnight at 37oC in 5% CO2 with or without 400 ug of custom-made human 
recombinant TOP1 protein purified from baculovirus-infected insect cells (GenScript), to allow the 
mo-DC to internalize the protein, process it and present TOP1 peptides onto HLA-DR molecules. 
Isolation of HLA-DR- peptide complexes. Antigen-pulsed mo-DCs were collected and washed with 
cold buffer A (PBS, 2 mM EDTA; pH 7.4-7.6). The cells were then lysed in cold buffer B (1% 
CHAPS, 1 mM EDTA, protease inhibitor cocktail) and incubated at 4o C on a rocking table for 15 
minutes. This lysis step was repeated, insoluble material removed by centrifugation, and the 
supernatant was incubated with Protein G Dynabeads (Thermo Fisher) coated with 20 ug of anti-
HLA-DR (clone L243, BioLegend) or isotype control (clone MOPC-173, BioLegend) antibodies  at 
4o C for one hour with inversion. The beads were then washed 4-times with lysis buffer B, and 3-
times with buffer C (20 mM Tris, 150 mM NaCl, pH 7.4). The HLA-DR-bound peptides were eluted 
by incubating the beads with 0.1% TFA for 1 minute at room temperature and harvesting the eluate. 
This step was repeated once and the pooled eluate was centrifuged through a 10kD centrifugal filter 
(Microcon, Millipore). The filter was washed with 0.1 % TFA and pooled flow-through containing 
the eluted peptides was lyophilized by vacuum centrifugation. The peptides were then analyzed by 
mass spectrometry, as described in detail in the online supplementary material and methods. 
HLA-DRB1 genotyping and sequence alignment
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Whole blood was collected using PAXgene Blood DNA tubes and DNA was extracted 
according to manufacturer’s instructions (PreAnalytiX).  High-resolution HLA-DRB1 typing was 
performed by next generation sequencing at the Johns Hopkins University Immunogenetics 
Laboratory, as previously described (12). Amino acid sequences encoded for by the HLA-DRB1 
alleles of interest were obtained using the online IMGT/HLA submission tools (Immune 
Polymorphism Database)  (13). Peptide contact and pocket residues in each HLA-DRβ1 chain were 
identified using the online MHC motif viewer (14). Sequence alignment and consensus sequence 
visualization was performed using Jalview version 2.10.5 software (15). Affinity and register of 
peptides for HLA-DR variants was predicted using the online NetMHCII 2.3 algorithm (16).
Protein Structure Images
Linear mapping of TOP1 epitopes was plotted using R (R Core Team, 2018). The three-
dimensional location of TOP1 peptides within the TOP1 protein crystal structure (1K4T) and location 
of consensus peptide binding motifs within HLA-DR11 (6CPN) was visualized using the PyMOL 
Molecular Graphics System, version 2.3 (Schrödinger, LLC).
T cell stimulation
PBMCs from ATA-positive (n=11) and ATA-negative (n=11) patients with scleroderma were 
isolated by Ficoll density-gradient centrifugation (Ficoll-Paque Plus, GE Healthcare). The cells were 
resuspended to 1.5 × 106 cells/well in RPMI medium supplemented with 5% autologous serum, as 
previously described (9). Briefly, PBMCs were pre-incubated with anti-human CD40 blocking 
antibody (1 ug/ml; G28.5, BioLegend) prior to stimulation for 18 hours with 2.5 uM of each candidate 
TOP1 peptide (Table 1; >95% purity, Genscript), or 1.45 ug/mL human recombinant TOP1 protein 
(Genscript). Following stimulation, cells were stained with BV510-conjugated anti-CD3 (OKT3, 
BioLegend), Pacific Blue-conjugated anti-CD4 (RPA-T4, BD Pharmingen), APC-H7-conjugated anti-
CD8 (SK1, BD Biosciencies), PE-conjugated anti-CD154 (TRAP1, BD Pharmingen), and Live/Dead 
Fixable Stain (Molecular Probes). The percentage of live CD4+ T cells that upregulated CD154 were 
quantified by flow cytometry (FACSAria, BD Biosciences; FCS Express software, De Novo 
Software). A cutoff of greater than the 95th percentile of the responses observed amongst the ATA-A
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negative patients (%CD154+CD4+Tcells > 0.015%) was used to define a positive CD4+ T cell 
response to antigen stimulation.
Statistical analyses
Naturally presented peptides were analyzed using the PANTHER 14.1 gene list analysis tool 
statistical overrepresentation test for “biological processes” to identify if presented peptides were 
enriched in proteins belonging to specific biological processes (17). The “GO biological processes 
complete” annotation set was queried and the FDR and Fisher’s exact p-value for each pathway was 
calculated. The median number of peptides eliciting positive responses in ATA-positive versus ATA-
negative patients was compared using a Mann-Whitney test. The association between minimum FVC 
and the number of stimulatory TOP1 epitopes was analyzed using the Spearman’s rho test. The 
association between minimum FCV and the percentage of TOP1-specific CD154+CD4+ T cells was 
analyzed using the Pearson’s r. Statistical analyses were performed using Prism version 7.03 
(Graphpad) and Stata version 14.2 (Stata Corp) software. Statistical significance was defined as a 
two-sided p-value ≤0.05 throughout.
Results 
Identification of naturally presented TOP1 peptides 
We developed a natural antigen processing assay (NAPA) to identify TOP1 peptides presented 
by MHC class II molecules expressed on APCs from patients with scleroderma. As a source of 
patient-specific APCs, monocytes were isolated from the peripheral blood of 6 ATA-positive patients 
with scleroderma and cultured in the presence of GM-CSF and IL-4 to generate monocyte-derived 
dendritic cells (mo-DCs). Mo-DCs were then incubated withwhole TOP1 protein overnight, to allow 
for internalization and processing of the protein and presentation of TOP1 peptides by the HLA-DR 
molecules present on these patient-specific APCs (Figure 1). HLA-DR-peptide complexes were 
isolated by anti-HLA-DR immunoprecipitation, and presented peptides were eluted and sequenced by 
mass spectrometry.A
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NAPA identified hundreds of naturally processed peptides derived from the exogenously 
added TOP1 protein, as well as from other endogenous self-proteins derived from the mo-DCs 
(Figure S1, Table S2). The median length of these peptides was 15 amino acids, and clustering of 
variable length peptides into nested sets around a common core sequence was observed (Table S2). 
These are features typical of naturally processed MHC class II peptides, which tend to be 13-25 
amino acids long and exist in nested sets  (18,19).  As expected, the naturally processed peptides were 
enriched in those derived from proteins expected to traffic through the secretory pathway, where 
MHC class II antigen processing occurs (Figure S1C). This includes a global enrichment in peptides 
derived from proteins involved in antigen processing itself (Figure S1B). Analysis of the peptides 
presented between individuals revealed common presentation of peptides derived from membrane-
associated (e.g. ITGAM and MRC1) and secreted proteins (e.g. TGFBI and TIMP3), as well as other 
MHC molecules.  Importantly, the only antigen commonly presented by all 6 patients was the pulsed 
antigen, TOP1, demonstrating the ability of NAPA to detect peptides from endocytosed proteins. The 
specificity of NAPA for detecting HLA-DR-bound peptides, including those derived from TOP1, was 
confirmed using unpulsed mo-DCs and isotype control antibodies for immunoprecipitation (Tables S3 
and S4). In these experimental conditions, no TOP1 peptides were detected.
Remarkably, we observed substantial overlap in the TOP1 peptides presented by ATA-
positive scleroderma patients, with all subjects presenting peptides originating from only 10 discrete 
regions of the TOP1 molecule (Figure 2A). The median number of putative regions presented by each 
individual patient was 4 (range 1-7), and 70% were presented by at least two subjects.  The 10 regions 
from which TOP1 peptides were presented are from diverse domains of TOP1 and largely reside 
within structural elements, most dominantly alpha helices flanked by unstructured loops on the 
surface of the TOP1 protein (Figure 2A and B). The localization of putative TOP1 epitopes within 
structural elements adjacent to flexible loops is similar to what has been observed for CD4+ T cell 
epitopes from other infectious and self-antigens (20,21). Using NAPA, we successfully identified a 
common set of TOP1 peptides derived from the whole TOP1 protein, which were naturally processed 
and presented by HLA-DR molecules in mo-DCs generated ex vivo from patients with ATA-positive 
scleroderma. 
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Shared motifs present in HLA-DRβ chains of patients with ATA-positive scleroderma  
We next performed HLA typing to determine if the presentation of common TOP1 peptides 
identified in our patients was due to the presence of shared HLA-DRB1 alleles. Despite the known 
association of ATA with specific HLA-DRB1 alleles (i.e. HLA-DRB1*11:01, *11:04, *08:02, *08:04, 
or *15:02) (4), only 3 subjects (50%) harbored a previously defined risk allele. While these 3 patients 
concurrently presented peptides from more regions of the TOP1 molecule compared to those who did 
not carry a known ATA-associated allele (median 6 vs. 1), common peptides were presented 
regardless of the allele status. 
Given this unexpected ability of diverse HLA-DR variants to present common TOP1 peptides, 
we sought to determine if similar features were present in the HLA-DRβ chains of ATA-positive 
scleroderma patients. To explore this, we performed amino acid sequence alignment of the HLA-DRβ 
variants linked to the development of ATA-positive scleroderma (4) and compared them to the HLA-
DRβ chains in these patients. This analysis revealed two conserved motifs within the DRβ-chain 
encoded for by the HLA-DRB1 alleles most strongly linked to ATA (22–25) (HLA-DRB1*08:02, 
*08:04, *11:01, *11:04): 9E-Y-S-T-S/G-E14 and 67F-L-E-D-R-R-A-A/L74  (Figure 3A).  HLA-
DRβ1*15:02, associated with ATA in Asian populations (4), had a similar 67I-L-E-Q-A-R-A-A74 
motif but a distinct sequence at position 9-14 (9W-Q-P-K-R-E14) (Figure 3A). Importantly, these two 
motifs contain key peptide contact residues at positions 9, 11, 13, 14 and 67, 70, 71, 74 respectively 
(Figure 3B). 
Analysis of the HLA-DRβ chains present in patients who did not have previously defined 
ATA-associated HLA-DRB1 alleles, but were able to present common TOP1 peptides, revealed 
several conserved features.  HLA-DRβ1*15:01 and *16:01 contained motifs at positions 9-14 and 67-
74 that were identical to known ATA-associated alleles (Figure 3A). HLA-DRβ1*04:01 and *04:02 
were less similar, but had conserved amino acids at known peptide contact positions (i.e. 9, 14, and 
67, 70, 74). A more detailed analysis of β-chain residues that comprise the five major peptide binding 
pockets in the HLA-DR groove (denoted as P1, P4, P6, P7, and P9) confirmed that ATA-associated 
and homologous alleles have highly similar peptide binding pockets (Figure 3C). Interestingly, HLA- 
DRβ1*09:01 and *07:01 were divergent from ATA-associated alleles at several critical peptide 
contact residues (Figure 3, A and C), and HLA- DRβ1*07:01 has been reported to be protective A
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against scleroderma development (26). While all the ATA-positive patients in our study possessed at 
least one allele that contained ATA-associated motifs, those who harbored HLA- DRβ1*09:01 and 
*07:01 presented the fewest number of TOP1 peptides (Figure 2A). These data reveal shared features 
in the peptide binding grooves of seemingly unrelated HLA- DRβ1 variants present in ATA-positive 
patients with scleroderma, providing a mechanism for the shared presentation of common TOP1 
peptides.
Promiscuous binding of TOP1 peptides to multiple HLA-DR variants
To examine the intermolecular interactions between the commonly presented TOP1 peptides 
identified using NAPA and the HLA-DR variants detected in these patients, we used the NetMHCII 
2.3 algorithm to predict the peptide binding affinity and register (16).  Since all of the patients were 
heterozygous at the HLA-DRB1 locus, we examined the predicted binding of peptides to both HLA-
DR variants present in a given individual. This analysis revealed peptides that could be categorized 
into two distinct groups, termed group A and B, based on their predicted binding register (Figure 4). 
Group A peptides (peptides 1, 2, 8, 9, and 10) were predicted to bind in the same register to all 
associated HLA-DR variants (Figure 4A). This is in contrast to group B peptides, which were 
predicted to bind in different registers to multiple different HLA-DR variants (Figure 4B). Group A 
peptides were also predicted to bind with significantly lower affinity to their respective HLA-DR 
molecules than Group B peptides (4421 ± 1184 vs. 535 ± 276 nM, respectively; p=0.013, Table S5), 
and were presented by fewer individuals than group B peptides (median 1 vs. 3). This suggests that 
group A peptides are relatively weak-binding peptides that contain a single core epitope (e.g. 
LMKLEVQAT in peptide 10) whose anchor residues interact with shared features present in the 
HLA-DR binding grooves of patients with ATA. In contrast, group B peptides appear to contain 
multiple distinct epitopes, each possessing a unique set of anchor residues that enable high-affinity 
interaction with a more diverse set of HLA-DR binding pockets (e.g. LSYNRANRA, ILSYNRANR, 
and YNRANRAVA in peptide 7). Taken together, these data support a model of convergent TOP1 
peptide presentation in patients with scleroderma driven by shared peptide-binding motifs in the 
HLA-DR groove and a promiscuous group of TOP1 peptides.
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Robust recognition of commonly presented TOP1 epitopes by CD4+ T cells in scleroderma
The discovery of a shared mechanism for the presentation of a core set of TOP1 peptides 
suggests that these epitopes may be central to the disease process in patients with scleroderma. To 
determine if these epitopes are immunologically relevant in ATA-positive patients, we synthesized 10 
peptides corresponding to the putative TOP1 epitopes identified using NAPA (Figure 2A; Table 1) 
and examined their ability to stimulate CD4+ T cells from 11 ATA-positive and 11 ATA-negative 
scleroderma patients (clinical variables are shown in Table S1). CD4+ T cell activation, as measured 
by upregulation of the early activation marker CD154 (9,27), was observed in response to at least one 
TOP1 peptide in 73% (8/11) of ATA-positive patients compared to 27% (3/11) of ATA-negative 
individuals (Figure 5A, Table S6).  ATA-positive patients also responded to significantly more TOP1 
epitopes (median 2 vs. 0; p=0.02) (Figure S2A). This was most pronounced in ATA-positive subjects 
with known disease-associated HLA-DRB1 alleles, compared to those without (median 7 vs. 1.5 
epitopes, respectively), and recognition of group A and B peptides was observed regardless of ATA-
associated allele status. Importantly, the increased T cell responses observed in ATA-positive 
compared to ATA-negative patients were not due to differences in exposure to immunosuppressive 
medications (Table S1).
For 6 out of the 11 ATA-positive patients (54%), the combined frequency of CD154+ cells 
observed in response to the individual TOP1 peptides (Figure S2, B and C) was comparable to that 
measured in response to the whole TOP1 protein. This suggests the immunodominance of this set of 
10 naturally processed TOP1 peptides in these individuals.  Robust recognition of a core set of TOP1 
epitopes in immunogenetically diverse ATA-positive patients supports our observation that features 
on both sides of the peptide-MHC interaction contribute to the development of anti-TOP1 immune 
responses in patients with scleroderma.
Diversity of TOP1-specific T cell responses associated with ILD severity
ATA-positive scleroderma is associated with diffuse skin involvement and ILD (3). Therefore, 
we explored whether the presence of TOP1-specific T cells is associated with either of these clinical 
characteristics. We evaluated the responses to both the whole TOP1 protein and the number of TOP1 
epitopes recognized by T cells in relation to the type of skin involvement, but no significant A
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association was found (Figure S3). We then sought to investigate if there is any correlation with 
scleroderma lung disease. We evaluated the lowest forced vital capacity (FVC) recorded during the 
course of clinical follow-up for each patient as a measure of the severity of lung fibrosis. We focused 
this analysis on the 9 ATA-positive patients with radiographically defined scleroderma-associated 
ILD. A significant negative association was observed between the minimum FVC and the number of 
TOP1 epitopes that elicited a T cell response (p=0.025; Figure 5B). While this relationship was also 
observed in response to whole TOP1 protein (p=0.002; Figure 5C), it is remarkable that these 10 
commonly presented epitopes were sufficient to identify T cell responses associated with more severe 
lung disease. This implicates CD4+ T cells targeting commonly presented TOP1 epitopes in the 
pathogenesis of scleroderma-ILD. 
Discussion 
This investigation sought to evaluate one of the most proximal events in the stimulation of 
autoreactive TOP1-specific T cells, the presentation of autoantigenic epitopes by ATA-associated 
HLA-DR variants. Our study supports two parallel and complementary mechanisms for how unique 
features present on both sides of the “peptide-HLA-DR interaction” synergize to promote the 
presentation of common epitopes, which drive the development of convergent immune responses and 
clinical characteristics. Together with the observation that the breadth of the CD4+ T cell responses to 
these TOP1 epitopes is associated with presence and severity of lung fibrosis, these findings offer 
novel insights into the pathogenesis of scleroderma.
The identification of common TOP1 epitopes enabled the definition of two distinct groups of 
TOP1 peptides that differ in their interaction with HLA-DR. Group A TOP1 peptides contain a single 
core epitope that is bound in the same register to multiple HLA variants, likely interacting with shared 
features in the peptide binding groove. Group B TOP1 peptides, however, contain multiple distinct 
epitopes that utilize different anchor residues to bind promiscuously to diverse HLA variants. This 
suggests that features intrinsic to the peptide binding groove are responsible for presenting of Group 
A peptides, while presentation of Group B peptides is largely driven by peptide-intrinsic features. 
Analysis of the peptide binding grooves of seemingly unrelated HLA-DR variants indeed A
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demonstrated the existence of shared motifs(9E-Y-S-T-S/G-E14 and 67F-L-E-D-R-A-A/L74) found in 
patients with ATA-positive scleroderma, which enabled the presentation of a common set of TOP1 
epitopes. Importantly, the 67F-L-E-D-R71 motif was previously identified by Kuwana et al. in 1993 
and hypothesized to be a common feature of alleles associated with ATA in different ethnicities 
(23,24,28), but the mechanism for this was unknown. Our data provide direct evidence that the 
presence of HLA-DR variants containing these or homologous sequences is associated with the 
increased presentation and recognition of TOP1 epitopes. Our finding of shared motifs in seemingly 
diverse HLA-DRB1 alleles in scleroderma is analogous to the “shared epitope hypothesis” in 
rheumatoid arthritis  (29,30), in which a conserved amino acid sequence (70R/Q-R/K-R-A-A74) 
present in the HLA-DRβ chain of a group of HLA-DR variants is hypothesized to lead to the 
presentation of common “arthritogenic” self-peptides (31), though this has not been directly 
demonstrated in patients. While the collective analysis of alleles carrying a common motif has not yet 
been widely adopted for genetic studies in scleroderma, our data provides strong evidence for a shared 
epitope-like motif in scleroderma and bolsters the rationale for the use of such analyses in future 
studies. 
While this mechanism may be dominant in patients who harbor ATA-associated risk alleles, 
scleroderma can also develop in patients who lack these HLA-DRB1 alleles. Our discovery of a group 
of promiscuous TOP1 peptides provides a potential mechanism for how the development of immune 
responses to TOP1 could by-pass the need for these risk alleles. While promiscuous peptides have 
been described in the setting of cancer, infection, and mouse models of autoimmunity  (32–36), to our 
knowledge such peptides have not been described to be naturally presented in patients with 
autoimmunity. Further biophysical studies are required to define the precise anchor residues 
responsible for presentation of promiscuous TOP1 peptides in scleroderma, and to determine if this 
mechanism is operative in other autoimmune diseases.
In addition to our study, other approaches have been taken to define TOP1 specific T cell 
epitopes in patients with scleroderma. Using 6 large overlapping fragments spanning the entire TOP1 
protein, Kuwana et al. was the first to define DR-restricted immunologic hot-spots within the TOP1 
protein  (37,37). Through a series of experiments, they determined that amino acids 276-386 
contained an epitope that could stimulate T cell proliferation in healthy controls and patients with A
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scleroderma irrespective of HLA-DR allele or ATA status, and additional fragments (amino acids 
363-563 and 541-657) were also able to stimulate robust responses in individuals with specific HLA 
alleles (5,37). Interestingly, these three regions contain the group B peptides defined in our study 
(peptides 3, 4, 5, 6, and 7), as well as one group A peptide (peptide 2). Consistent with our results, 
TOP1 fragments of the N- (amino acids 1-93) and C-termini (amino acids 658-765) were less broadly 
stimulatory. Building on this work, Veeraraghavan et al. found that 3 in silico predicted TOP1 
peptides derived from these hot-spots were able to stimulate T cell proliferation in patients with 
scleroderma, one corresponding to peptide 6 and two others not identified in our study (amino acids 
373-387 and 641-656) (7). Using a different approach, Hu et al. created an overlapping peptide library 
of 15mer peptides spanning the entire TOP1 protein sequence and used this to define the epitope 
specificity of T cell clones derived from patients with scleroderma and healthy controls (8). They 
found 13 distinct epitopes identified to cause clonal T cell expansion, three of which were also 
identified in our study (peptides 4, 8, and 9). 
There are several important points that emerge from these comparisons. The first is that while 
T cell responses were observed to TOP1 peptides in all studies, ours is the only one to have found an 
association with clinical indices of ATA-positive scleroderma. This could, in part, be due to 
differences in the assays used to study T cell responses: upregulation of the early activation marker 
CD154 in our study and cell proliferation in the other three studies. Upregulation of CD154 is highly 
specific for TCR engagement with cognate antigens and not influenced by non-specific stimuli, 
whereas cell proliferation can have high background depending on the background proliferative 
capacity of the donor and length of stimulation (38). This may also explain why we found T cell 
responses to TOP1 peptides to be highly enriched in ATA-positive vs. -negative patients, whereas the 
other studies did not. Lastly, while our study identified clinically meaningful set of TOP1 epitopes, 
this does not represent all of the TOP1 epitopes capable of driving pathogenic anti-TOP1 immune 
responses in scleroderma. The finding of T cell responses to TOP1 peptides in other studies not 
detected using NAPA may reflect a finite sensitivity of the assay, but may also suggest additional 
TOP1 epitopes could be revealed by studying the processing of TOP1 by other APCs.  While 
dendritic cells are most effective at initiating T cell responses, other APCs like macrophages and B 
cells express MHC class II and have the ability to present CD4+ T cell epitopes (39). Differences in A
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the presented peptide repertoire may differ by the type or anatomical site of the APC (40,41), 
suggesting that additional TOP1 epitopes could be revealed by studying the processing of TOP1 by 
other APCs.  
The pathogenic relevance of convergent TOP1 epitope presentation in patients with 
scleroderma is illustrated by the detection of TOP1-specific CD4+ T cell responses to this core set of 
epitopes in >70% of patients with ATA-positive scleroderma. In our previous work, we have shown 
that the frequency of TOP1-specific CD4+ T cells is associated with the severity of lung fibrosis (9). 
This new study extends that observation by defining the epitope-specificity of these autoreactive T 
cells and demonstrating that the number of TOP1 epitopes recognized by a patient inversely 
associates with lung function. While unique HLA-DR variants have been linked to scleroderma 
development, ATA positivity, and ILD (42), the mechanism for this has not been directly 
demonstrated. Importantly, HLA-DRB1*11:01 was shown to be significantly associated with ILD 
only in the presence of ATA (43). Together with the evidence provided by our study, this suggests a 
model where specific HLA variants are mechanistically linked to the development of scleroderma 
ILD via activation of TOP1-specific autoreactive T cells, which provide help to autoreactive B cells 
and drive the development of ATA. 
Tetramers made from MHC molecules bound to antigenic peptides can be used to identify, 
track, and study antigen-specific immune responses over time in peripheral blood, as well as target 
tissues  (44). TOP1 tetramers containing epitopes identified in our study could therefore be developed 
as a precise tool to study the frequency and phenotype of TOP1 specific T cells ex vivo. Longitudinal 
studies in early scleroderma cohorts are needed to define whether the repertoire of TOP1 epitope-
specific CD4+ T cells changes over time and predicts onset or progression of fibrotic lung disease. By 
leveraging recent advances in medical bioengineering (45), these TOP1 epitopes may also be utilized 
for the future development of novel antigen-specific nanoparticle therapies aimed at downregulating 
TOP1-specific CD4+ T cell responses in patients with scleroderma. Precise definition of 
autoantigenic epitopes is therefore critical to understanding the primordial mechanisms for the loss of 
tolerance, studying disease-propagating autoreactive T cells, and developing antigen-specific clinical 
tools.
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Figures: 
Figure 1. Natural Antigen Processing Assay (NAPA).  MoDCs from 6 donors with ATA-positive 
scleroderma were incubated with whole TOP1 protein overnight (O.N.) at 37°C. Cells were then lysed 
and the peptide:HLA-DR complexes isolated by immunoprecipitation using magnetic beads coated 
with anti-HLA-DR antibodies (clone L243). The presented peptides were dissociated from the HLA-
DR molecules using 0.1% TFA and separated from HLA-DR molecules using a 10kDa spin filter, 
which allows the smaller molecular weight peptides to pass through. The filtered peptides were then 
identified and sequenced by liquid chromatography with tandem mass spectrometry (LC-MS/MS).
Figure 2. A common set of naturally processed TOP1 peptides was presented by scleroderma 
patients with diverse HLA-DR variants (A) The HLA-DRB1 haplotype for each patient is given and 
each colored line represents a unique TOP1 peptide sequence identified by mass spectrometry. The 
location of the TOP1 peptides within the linear TOP1 protein sequence is indicated. TOP1 protein 
domains and secondary structure elements are shown (β-strands and α-helices are represented by 
arrow heads and ovals, respectively). (B) The location of the naturally processed TOP1 peptides 
within the three-dimensional crystal structure of the TOP1 molecule bound to DNA (1K4T) is 
indicated. The peptides are colored-coded and correspond to the colors used in panel A.
Figure 3. Presentation of common TOP1 peptides linked to shared ATA-associated motifs in the 
HLA-DRβ chain. (A) Amino acid sequence alignment of ATA-associated (top panel) and non-
associated alleles (bottom panel) is shown. The two consensus sequences identified in the peptide-
binding groove of ATA-associated alleles are shown (middle panel). Peptide contact residues in the 
DRβ chain are shown (hydrophobic=blue, negative=purple, positive=red, polar=green, 
glycine=orange, prolines=yellow, and aromatic=cyan) and their position within the sequence is 
numbered, while intervening residues are shown in gray.  The white text indicates non-conserved 
residues. (B) A depiction of HLA-DR11 crystalized with a peptide (6CPN) is shown and features of 
the peptide binding groove have been color-coded: DR α-chain residues (light gray), DR β-chain 
(dark gray) and peptide (magenta). The 9E-Y-S-T-S/G13 and 67F-L-E-D-R-R-A-A/L74 motifs are 
shown in cyan and yellow, respectively. (C) Peptide contact residues for each MHC binding pocket A
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and the relevant consensus sequence for ATA-associated (light blue), homologous (orange) and 
heterologous (black) alleles are represented. Different shades of gray indicate the importance of each 
residue to peptide binding, with dark gray being the most critical.
Figure 4. Allele-specific TOP1 peptide binding registers may contribute to promiscuous 
presentation by diverse HLA-DR variants. (A) Group A TOP1 peptides (peptides 1, 2, 8, 9 and 10) 
and (B) group B TOP1 peptides (peptides 3, 4, 5, 6 and 7) are aligned according to their predicted 
binding registers as per NetMHCII algorithm with relevant anchor residues highlighted in gray. The 
HLA-DRB1 alleles are color-coded as ATA-associated (light blue), homologous (orange) and 
heterologous (black) alleles, and ordered from highest to lowest predicted affinity for each peptide. 
TOP1 peptides with a predicted binding affinity of <500 nM are indicated with red text, and are 
expected to represent moderate to high affinity peptides.
Figure 5. Distribution and clinical significance of CD4+ T cell responses to naturally presented 
TOP1 epitopes in scleroderma. (A) %CD154+CD4+ T cell responses over background observed 
with media alone for 11 ATA-positive and 11 ATA-negative scleroderma patients for each of the 10 
naturally processed TOP1 peptides identified using NAPA are shown. The dotted line represents the 
cutoff for positivity that was defined as >95th percentile of the T cell responses observed in ATA-
negative patients (95th percentile=0.015%). Each unique colored symbol represents a different patient. 
The minimum FVC (% of expected) was plotted against (B) the number of TOP1 epitopes eliciting a 
T cell response and (C) the percentage of CD154+CD4+ T cells responses elicited against the whole 
TOP1 protein in ATA-positive scleroderma patients with clinically documented ILD (n=9). The 
correlation between minimum FVC and the number of stimulatory TOP1 epitopes was analyzed using 
a Spearman’s rho test, and the correlation with the magnitude of the T cell responses to the TOP1 
protein was analyzed using a Pearson’s r test. A p-value <0.05 was considered significant throughout.
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Table 1. TOP1 peptides corresponding to the TOP1 regions identified by NAPA
Peptide TOP1 RESIDUES TOP1 PEPTIDE SEQUENCE
1 127-145 VPPKEDIKPLKRPRDEDDA
2 279-292 KDWRKEMTNEEKN
3 304-318 TQMSQYFKAQTEARKQ
4 422-438 GSIKYIMLNPSSRIKGEK
5 517-536 DGQEYVVEFDFLGKDSIRY
6 585-606 TAKVFRTYNASITLQQQLKELTA
7 606-627 APDENIPAKILSYNRANRAVAI
8 659-676 DARRDLKSAKADAKVMK
9 676-696 KDAKTKKVVESKKKAVQRLEE
10 696-713 EQLMKLEVQATDREENKQ
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